From next month a medication for a rare and potentially deadly genetic condition with be available through the Pharmaceutical Benefits Scheme.
The federal government is listing Takhzyro for patients with hereditary angioedema, a condition that occurs in around one in 50,000 people.
angioedema results from a defect in the gene that controls a blood protein called C1-inhibitor and leads to higher levels of a substance called bradykinin in the bloodstream, which causes symptoms such as swelling and pain.
Health Minister Greg Hunt said this new listing would benefit more than 100 Australians each year.
"Without this PBS subsidy, Australian patients are paying around $241,000 per year for this treatment," Mr Hunt said in a statement on Sunday.
"From December 1, they'll pay $41.30 per script or $6.60 with a concession card."
